Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Theralase Technologies ( (TSE:TLT) ) has shared an update.
Theralase Technologies announced that its interim clinical data on the light-activated Ruvidar™ for treating BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) carcinoma in-situ will be presented at the 2025 American Urological Association Annual Meeting. This data highlights the treatment’s safety and efficacy, offering a potential significant advancement in bladder cancer therapy for patients with limited options. The treatment has shown promising results, with some patients experiencing a durable response of three years or more, potentially revolutionizing the treatment landscape for bladder cancer and allowing patients to avoid radical cystectomy.
More about Theralase Technologies
Theralase Technologies Inc. is a clinical-stage pharmaceutical company focused on the research and development of light, radiation, sound, and drug-activated small molecules. The company’s primary aim is to provide safe and effective treatments for various cancers, bacteria, and viruses.
YTD Price Performance: -9.09%
Average Trading Volume: 97,772
Technical Sentiment Consensus Rating: Sell
Current Market Cap: C$61.95M
Learn more about TLT stock on TipRanks’ Stock Analysis page.
